Results for savor translation from English to Maltese

savor trial results
riżultati tal-prova savor

table 3 primary and secondary clinical endpoints by treatment group in the savor study*
tabella 3: punti ta’ tmiem kliniċi primarji u sekondarji skont il-grupp ta’ kura fl-istudju savor

the savor trial included 8240 patients treated with onglyza 5 mg or 2.5 mg once daily and 8173 patients on placebo.
il-prova savor inkludiet 8240 pazjent ikkurati b’onglyza 5 mg jew 2.5 mg darba kuljum u 8173 pazjent fuq plaċebo.

in the savor study subgroups over 65 and over 75 years of age, efficacy and safety was consistent with the overall study population.
fis-subgruppi tal-istudju savor fuq persuni li għandhom aktar minn 65 sena u persuni li għandhom aktar minn 75 sena, l-effikaċja u s-sigurtà kienu konsistenti mal-popolazzjoni tal-istudju ġenerali.

saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus - thrombolysis in myocardial infarction (savor) study
valutazzjoni ta' saxagliptin ta' riżultati vaskulari irreġistrata f'pazjenti bid-dijabete mellitus - tromboliżi fi studju tal-infart mijokardijaku (savor).

in the savor trial a small increase in the rate for hospitalisation for heart failure was observed in the saxagliptin treated patients compared to placebo, although a causal relationship has not been established (see section 5.1).
fil-prova savor, kienet osservata żieda żgħira fir-rata ta’ rikoveru l-isptar għal insuffiċjenza tal-qalb fil-pazjenti ikkurati b’saxagliptin meta mqabbel ma’ plaċebo, għalkemm ma ġietx stabbilita relazzjoni kawżali (ara sezzjoni 5.1).